Treace Medical Concepts (TMCI)
(Delayed Data from NSDQ)
$6.18 USD
+0.20 (3.34%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $6.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Treace Medical Concepts (TMCI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.86 | $17.00 | $7.00 | 48.16% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Treace Medical Concepts comes to $8.86. The forecasts range from a low of $7.00 to a high of $17.00. The average price target represents an increase of 48.16% from the last closing price of $5.98.
Analyst Price Targets (7 )
Broker Rating
Treace Medical Concepts currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on seven recommendations.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TMCI.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 7 | 7 | 7 | 7 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/16/2024 | UBS | Danielle Antalffy | Strong Buy | Hold |
5/8/2024 | BTIG | Ryan Zimmerman | Strong Buy | Hold |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Hold |
1/16/2024 | Stephens | George Sellers | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 7 |
Average Target Price | $8.86 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.27 |